Allergy, Immunology, and ENT

Latest News

Image Credit: © Elena Medoks - © Elena Medoks - stock.adobe.com.
Viaskin milk patch demonstrates mixed results, phase 1/2 data shows

March 1st 2024

Viaskin milk patch shows promise in cow’s milk allergy, particularly in children aged 2-11 with 300 μg dose, though the other doses examined failed to prove significant benefit.

Robert Wood, MD | Image Credit: Hopkinsmedicine.org
Experts share their thoughts on the omalizumab OUtMATCH phase 3 data

February 29th 2024

Long-term safety of epicutaneous immunotherapy with DBV712 for peanut allergy | Image Credit: © Stepan Popov - © Stepan Popov - stock.adobe.com.
Long-term safety of epicutaneous immunotherapy with DBV712 for peanut allergy

February 27th 2024

Omalizumab increases reaction threshold for multiple common food allergies | Image Credit: © Yulia - © Yulia - stock.adobe.com.
Omalizumab increases reaction threshold for multiple common food allergies

February 26th 2024

Thomas Casale, MD
Neffy for patients with anaphylactic symptoms after oral food challenge

February 23rd 2024

Latest CME Events & Activities

Earn CME Credits While Advancing Your Expertise in Internal Medicine

April 18-19, 2024

Register Now!

Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes

View More

Community Practice Connections™: Preparing for an Expanded Armamentarium for Food Allergy

View More

Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma

View More

Advances In: Integrating New Treatment Options into Management Plans for Patients with Moderate-to-Severe Atopic Dermatitis

View More

Medical Crossfire®: Maximizing Patient Outcomes in Shingles – Are You Leveraging Guideline Based Care?

View More

Respiratory Syncytial Virus: Understanding the Infection Burden and Anticipating the Impact of Vaccines

View More

(COPE Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME

View More

Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!

View More

(CME Credit) Community Practice Connections™: Keeping an Eye on Evolving Management Strategies for nAMD and DME

View More

Cases and Conversations™: Enhancing Diagnosis and Management of Patients with Autoimmune Hemolytic Anemia

View More

Addressing Healthcare Inequities™ in Glaucoma Management – Understanding Challenges in Segmented Patient Populations (CME Track)

View More

Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care

View More

Community Practice Connections™: Enhancing Diagnosis and Management of Patients with Autoimmune Hemolytic Anemia

View More

Cases and Conversations™: Evidence-Based Approaches to Management of CKD in Your Patients with T2DM

September 25, 2024

Register Now!

Collaborating Across the Continuum™: The Role of Multidisciplinary Care in the Management of Patients with Exocrine Pancreatic Insufficiency

View More

Mastering MS: Translating Evidence into Optimal Management Plans

View More

3rd Annual International Congress on Pediatric Oncology

October 25, 2024

View More

Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes

View More

Patient, Provider, and Caregiver Connection™: Prevention and Control of Meningococcal Disease — Individualizing Vaccine Recommendations in Adolescent Populations

View More

Let’s Get “Real”: Alpha-1 Antitrypsin Deficiency—Case-Based Perspectives on Managing Associated Emphysema

View More

Shaping the Management of COPD with Biologic Therapy

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Advances In™ Rare Genetic Forms of Obesity: Emerging Therapeutic Targets

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Comprehensive Approaches to Creating Successful Sickle Cell Management Plans Across Patients’ Lifespans

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients

View More

Overcoming Racial Disparities in Multiple Myeloma Outcomes and Clinical Trials: How We are Moving Care Forward Today

View More

More News


Site Logo

Wheeze in Preschool Children:

April 1st 2007

Severe disability and even death can result from the inappropriate diagnosis and treatment of a young child's wheezing, which is heterogeneous in its origins and expression. Consequently, a differential diagnosis is necessary to determine the cause and to develop an effective management strategy. Viral-induced wheeze, especially from respiratory syncytial virus (RSV), manifests as a bronchiolitis. Recent reports show that the cysteinyl leukotrienes are an important mediator of the airway effects of RSV infection and that leukotriene receptor antagonists reduce postrespiratory syncytial virus lung symptoms. Exercise-induced bronchoconstriction manifests as wheezing and can be treated or pretreated short-term with inhaled bronchodilators or cromolyn: long-term therapy includes inhaled corticosteroids and leukotriene receptor antagonists. Allergic rhinitis-associated wheeze may be the result of acute exposure to an allergen or simply from nasal dysfunction. Control of allergic rhinitis with intranasal steroids, antihistamines, or leukotriene receptor antagonists could relieve the wheezing. Asthma-associated wheeze requires long-term use of 1 or more daily controller medications. The primary goal is to navigate the child safely through the first episode of wheezing, consider the causes of the wheeze, and then evaluate the need for further therapy. All apparent causes of wheeze should be treated with the idea that if the apparent cause turns out not to be the actual cause, treatment can be safely discontinued.

© 2024 MJH Life Sciences

All rights reserved.